Table 5.
Ages 40 to 49 | Ages 50 to 54 | Ages 40 to 54 | ||||
---|---|---|---|---|---|---|
Group 1 Annual screening | Group 2 No screening | Group 1 No screening | Group 2 No screening | Group 1 Total | Group 2 Total | |
Base-case | ||||||
Screen-detected | ||||||
Invasive | 7772 | - | - | - | 7772 | - |
Progressive in situ | 1145 | - | - | - | 1145 | - |
Non-progressive in situ | 874 | - | - | - | 874 | - |
Clinically detected | ||||||
Invasive | 5693 | 14 089 | 7680 | 8151 | 13 373 | 22 240 |
Non-progressive in situ | 546 | 1336 | 658 | 728 | 1204 | 2064 |
All cancers | 16 030 | 15 425 | 8338 | 8879 | 24 368 | 24 304 |
Overdiagnosis | ||||||
Absolute number | 605 | -541 | 64 | |||
% of screen-detected | 6.2 | 0.7 | ||||
% of cancers diagnosed within ages 40 to 49 | 3.8 | 0.4 |
Estimates from the overdiagnosis model.